

# DeTectioN Inc.

## Business Plan

*Final Draft*

AI-Driven Veterinary, Mortuary, and Testing Business Automation Platform or Acquisition of Business.

### Patent application foundation

- U.S. Patent Application No. US23/18/141,374 and PCT/US23/20501 Application — Apparatus and Method for Detecting Matter and Micro-Organisms.
- U.S. Patent Application No. US26/19,532,226 and PCT/US26/14456 Application — Robots Self-Directed by Quantum Computing and Classical Algorithms for Autonomous Physical Procedures in Medical, Dental, Cosmetic, Dermatology, Ophthalmology, and Veterinary Applications.

Prepared for internal planning, investor discussions, lender presentations, and strategic partnership outreach.

April 2026

Detection Inc - A Delaware corporation incorporated in 2022 and in good standing. Owns automated intellectual property, quantum computing automated technologies and Intellectual property, hybrid technology IP, robotic, drone, watercraft, ai agent automation technology, all developed trade secrets, biosurfactant ai technologies, databases, and dot ai (.ai) domain names.

## At a Glance

<b>Company</b>	DeTecton Inc.
<b>Business model</b>	Acquire and integrate veterinary, mortuary, and testing facilities - deploy AI agents directing robots to centralize operations, utilize machine learning to automate workflow across the platforms.
<b>Core market</b>	Companion-animal, mixed-animal, equine, large-animal, herd-health, and field-service veterinary practices. Mortuaries and testing facilities.
<b>Technology focus</b>	Business workflow automation to train models for further human medical applications and procedures. Swam AI agent applications, micro-organism and matter detection systems, and future autonomous or semi-autonomous application with monitoring.
<b>IP foundation</b>	Pending US/ WIPO patent applications worldwide. Trade secrets complement IP and know how.
<b>Primary value creation</b>	Practice acquisition, margin improvement, decrease expenses through automation, proprietary tech platform, data assets, database revenues from cloud, and future technology licensing.

**DeTecton Inc. is designed to be more than a traditional company roll-up.** The company will acquire veterinary practices, mortuaries, and testing facilities and automate most aspects to strengthen them through a centralized operating platform and a proprietary AI stack that reduces administrative burden, improves speed and consistency, and builds defensible intellectual property over time. The company will not acquire farms or agricultural production assets; instead, it will develop veterinary AI agent applications for farm, field, herd-health, and large-animal veterinary use cases. After training is commenced with mortuaries, the technology platform will be deployed with medical examiners.

## 1. Executive Summary

DeTecton Inc. will acquire and integrate business and practices into a single AI-enabled holding company. The company will centralize finance, scheduling, reporting, procurement, client communications, data infrastructure, and management systems, then deploy AI agents and machine learning tools that improve speed, consistency, margin, and clinical support.

The target market is attractive because veterinary medicine remains fragmented, succession-driven, labor-constrained, and operationally under-automated. Many practices still depend on manual scheduling, fragmented medical records, inconsistent follow-up, underused technician capacity, and owner-dependent management processes. DeTecton Inc. is built to solve those weaknesses at scale.

The company's long-term advantage is not only operating efficiency but also a technology layer supported by pending patent applications. The first application covers the detection of matter and micro-organisms, and the second covers self-directed or autonomous physical procedures with veterinary applications. These filings support DeTecton Inc.'s roadmap for detection, workflow automation, and future robotic or semi-autonomous veterinary procedure assistance.

Quantum computing and quantum technologies (see February 2026 patent applications) will be slowly introduced to compliment classical computing technologies including the Universal Multi-Purpose Matter Detection AI "UMMDA". Quantum technologies will be utilized and trained for use in physical medical procedures and applications.

## 2. Market Need and Opportunity

Independent veterinary practices face a common set of structural pressures. Staffing shortages, rising compensation, increasing client expectations, manual record keeping, billing leakage, inconsistent patient follow-up, and aging ownership all reduce profitability and limit growth. Many clinics have strong demand but weak systems.

- Independent practice owners frequently need succession solutions, creating acquisition opportunities.
- Administrative work consumes doctor and technician time that should be used for care delivery and revenue-generating services.
- Field-service, herd-health, and large-animal veterinarians often work in mobile environments that still rely on fragmented paper or disconnected digital processes.
- Technology adoption in veterinary settings often remains piecemeal, leaving room for a platform approach that combines ownership, automation, and data intelligence.

## 3. Company Mission, Vision, and Structure

**Mission:** To modernize veterinary operations through AI-driven automation, detection systems, and data intelligence while preserving licensed professional oversight for clinical care.

**Vision:** To become the leading AI-powered holding company for veterinary care, veterinary workflow automation, and veterinary detection technologies.

**Structure:** DeTecton Inc. will serve as the parent holding company. Where state law or veterinary practice ownership rules require alternative structures, the company will use compliant management and ownership arrangements with licensed veterinary professionals and appropriate legal oversight.

## 4. Business Model

DeTecton Inc. will create value through three integrated layers:

- **Veterinary asset ownership:** acquire cash-flowing clinics and related service lines with operational improvement potential. Mortuary asset ownership where technology should ease workload and decrease expenses. Testing facilities will welcome the UMMDA for its automation and high accuracy with real time data. Real estate ownership should make funding a streamlined process.
- **Centralized operating platform:** move back-office functions, reporting, procurement, human resources support, and performance management into a standard corporate automated framework.
- **AI and application platform:** deploy AI agents, machine learning tools, detection applications, and future procedure-support technology across owned practices and later to third-party customers.

Revenue will come from veterinary services, diagnostics, surgery and procedures, preventive care plans, pharmacy and refill management, tele-support and follow-up workflows, and future software or technology licensing. Mortuaries will provide the training grounds for future human automated procedures and applications while generating revenues with basic services. Testing companies must use AI or become antiquated.

## 5. Acquisition Strategy

The company will focus first on smaller to mid-sized veterinary, mortuary, testing facility practices that can be integrated quickly and improved through disciplined operating upgrades. Geographic clustering will be prioritized when it supports management efficiency, referral growth, and brand scale.

Acquisition filter	What DeTection seeks	Why it matters
Ownership profile	Retiring, succession-driven, or under-managed owners	Creates realistic purchase conversations and transition potential
Practice type	Companion-animal, mixed-animal, equine, large-animal, or field-service practice	Supports broader veterinary platform and farm/field AI applications
Operations	Outdated systems, billing leakage, weak scheduling, manual reporting	Creates margin improvement opportunity
Team quality	Retainable veterinarians, technicians, and managers	Protects continuity and integration success
Financial profile	Stable demand with visible improvement potential	Supports acquisition financing and rollout of automation

## 6. Platform Services and Applications

DeTection Inc. will not replace licensed veterinary judgment. Instead, it will automate non-clinical and workflow-heavy processes, supply clinical decision support where appropriate, and create tools that increase throughput, consistency, and documentation quality.

### 6.1 Core clinic automation

- Scheduling, calendar optimization, reminders, and no-show reduction
- Digital intake, triage routing, chart preparation, and record summarization
- Billing, coding support, invoicing, collections workflow, and payment reminders
- Prescription and refill workflow support
- Inventory tracking, reorder prompts, and utilization reporting
- Client communications, recall campaigns, and post-visit follow-up

### 6.2 Veterinary farm and field AI agent applications

- Mobile field visit intake and dictation-to-record workflows. Automated AI buses/ semi trucks in 2027.
- Herd-health, vaccination, and treatment schedule coordination
- Large-animal follow-up reminders and compliance logging
- Remote symptom, anomaly, and environmental monitoring support
- Case routing and coordination between field staff and clinic staff
- Structured documentation for ranch, herd-health, equine, and mixed-animal service environments

## 7. Intellectual Property Foundation

DeTection Inc.'s strategic positioning is strengthened by two pending patent applications already associated with the founder's technology platform.

Application	Title	Planned business relevance
18/141,374	Apparatus and Method for Detecting Matter and Micro-Organisms	Supports veterinary detection products for samples, rooms, surfaces, equipment, contamination, and diagnostic-related workflows.
PCT/US26/14456	Robots Self-Directed by Quantum Computing and Classical Algorithms for Autonomous Physical Procedures in Medical, Dental, Cosmetic, Dermatology, Ophthalmology, and Veterinary Applications	Supports future procedure-support systems, autonomous or semi-autonomous workflow execution, robotic assistance, and advanced veterinary applications.

These are patent applications, not issued patents. In this business plan they are presented as an intellectual property foundation for commercialization, differentiation, and future licensing—not as a guarantee of issuance or regulatory clearance. Check filings for grants (South Africa, Kuwait - granted)

## 8. Technology Roadmap

The company's technology roadmap is staged so that early wins come from workflow automation and data standardization, while more advanced applications are developed over time.

- Phase 1: Deploy AI agents for intake, scheduling, client communication, documentation support, and reporting.
- Phase 2: Add structured analytics, risk scoring, anomaly detection, and multi-site operational dashboards.
- Phase 3: Launch detection products and applications grounded in the matter and micro-organism filing.
- Phase 4: Validate procedure-support tools and explore robotic or semi-autonomous applications grounded in the PCT filing, subject to technical feasibility, clinical validation, and regulatory pathway.

Every deployment will preserve veterinarian oversight. AI systems will be used to support workflows, generate recommendations, flag anomalies, and reduce manual burden. Clinical decisions, prescribing authority, and procedures requiring licensed professional judgment remain with qualified veterinary personnel.

## 9. Go-to-Market Strategy

Growth will come first from acquisition and same-site operating improvement. Once the software and applications are validated internally, DeTection Inc. can selectively commercialize them to outside practices.

- Acquisition outreach to retirement-age owners, brokers, and industry advisors
- Local growth through stronger branding, online scheduling, recall campaigns, and preventive care plans
- Cross-practice standardization of pricing discipline, collections, and technician utilization
- Future external licensing of selected AI tools to independent clinics, mobile veterinarians, and specialty providers

## 10. Operations Plan

The company will operate through a lean headquarters platform and strong local clinical leadership. Centralization will focus on systems and controls, while local teams preserve patient relationships, community trust, and licensed care delivery.

### 10.1 Headquarters functions

- Executive leadership and strategic planning
- Finance, accounting, treasury, and lender reporting
- M&A sourcing, diligence, and integration management
- Technology product management, data, and AI development
- Procurement, vendor management, and KPI dashboards
- Compliance coordination, insurance oversight, and policy management

### 10.2 Site-level functions

- Licensed professionals and veterinary/mortuary/testing technicians for training AI
- Practice managers and client service teams
- Field-service or mobile large-animal personnel where applicable
- Implementation champions responsible for training, adoption, and workflow feedback

## 11. Competitive Advantage

Capability	Clinic buyer	Software vendor	DeTection Inc.
Owens operating assets	Yes	No	Yes
Builds proprietary AI around live practice data	Limited	Varies	Yes
Captures margin gains from internal deployment	Some	No	Yes
Has application path for external licensing	Rarely	Yes	Yes
Combines acquisition, operations, and IP strategy	No	No	Yes

## 12. Funding Requirement and Use of Proceeds

DeTection Inc. will require outside capital for acquisitions, technology development, working capital, integration costs, and key hires. The exact size of the raise should be matched to target acquisition size, purchase structure, and lender availability. The table below shows an illustrative allocation framework.

Illustrative use of proceeds	Share
acquisitions and transaction costs	55%
AI/software development and data infrastructure	18%

operating runway of automation	10%
Integration, training, and system conversion	8%
Key hires, compliance, and insurance	6%
Business development and partnership outreach	3%

## 13. Milestones

Period	Primary objective	Milestones
0-12 months	Platform formation	Finalize acquisition criteria, complete first transaction, centralize reporting, deploy first workflow automations, and stand up implementation dashboards.
12-24 months	Integration and proof	Add additional sites, create regional operating discipline, standardize AI workflows, and produce measurable labor and collections improvements.
24-36 months	Commercialization readiness	Pilot detection-oriented applications, formalize product roadmap, and begin selective partnership or licensing conversations.
36+ months	Scale	Expand portfolio, deepen data advantage, and validate broader technology monetization strategy.

## 14. Risk Factors and Mitigation

Risk	Mitigation approach
Regulatory	Keep licensed veterinarians in charge of clinical judgment and use compliant ownership/management structures where required.
Integration	Use disciplined due diligence, retain key staff, and sequence systems conversion rather than forcing abrupt change.
Capital	Blend acquisition capital with seller financing, earnouts, and staged technology investment where possible.
Technology execution	Start with high-confidence workflow automation before expanding into advanced medical procedure-support products.
Cybersecurity/data	Use controlled access, vendor diligence, secure hosting, and formal privacy and incident-response policies.
Talent retention	Preserve local leadership, align incentives, and reduce burnout through automation relief rather than disruption.

## 15. Conclusion

DeTecton Inc. offers a differentiated strategy: acquire veterinary, mortuary, and testing facility practices, centralize operations, deploy AI agents across the portfolio, and build proprietary technology anchored in a pending autonomous-procedure patent filings worldwide. This combination can produce immediate operating improvements while creating long-term software and intellectual-property upside.

As a business plan, this document is intended to serve as a working draft for investors, lenders, legal counsel, acquisition targets, and strategic partners.

**Drafting note:** This plan intentionally describes the patent portfolio as pending applications and describes future autonomous or semi-autonomous veterinary, mortuary, and testing facility uses as roadmap concepts subject to implementation of technology.

## 16. Illustrative Funding Ask

For planning purposes, DeTecton Inc. may pursue an initial capital raise of approximately \$7.5 million. This amount is intended as an illustrative starting point for first acquisitions, platform build-out, and operating runway and should be refined against live targets, lender availability, and transaction structure.

- Illustrative security: IP grants international countries, or a negotiated structure with negotiated investor protections.
- Primary objective: complete 5 initial veterinary practice acquisitions, stand up centralized reporting and workflow systems, and fund the first wave of AI deployment.
- Leverage strategy: pair equity capital with seller financing, bank debt, real estate, or equipment financing when available in order to reduce dilution.
- Capital discipline: reserve adequate runway for post-close integration and avoid committing all proceeds to purchase price at closing.

### Illustrative capital plan

Capital component	Amount	Planning purpose
Practice acquisition and closing costs	\$4,500,000	Initial acquisition(s), diligence, legal, and transition expenses
AI platform and product development	\$1,250,000	Workflow automation, data infrastructure, pilot detection applications
Working capital and operating runway	\$900,000	Corporate overhead, early operating losses, and liquidity cushion
Integration, training, and systems conversion	\$500,000	EHR/process conversion, staff training, implementation support
Compliance, insurance, and contingency reserve	\$350,000	Regulatory, cybersecurity, professional fees, and reserves

**Note:** This is an illustrative funding framework only and should be updated once acquisition targets, lender terms, and capitalization preferences are known.

## 17. Executive Compensation Framework

Executive compensation should balance three goals: preserve cash during the early acquisition phase, align leadership with investor returns, and provide enough stability to recruit and retain qualified operators as the platform scales.

- CEO pay should remain moderate at formation and increase only as recurring revenue, integrations, and KPI targets are achieved.
- Annual incentives should be tied to objective metrics such as acquisition execution, revenue integration, EBITDA improvement, cash collections, and product milestones.
- Long-term equity or option awards should vest over time and be subject to board approval in order to align management with enterprise value creation.

## Illustrative senior leadership compensation ranges

Role	Year 1	Year 2	Year 3	Variable/equity
Chief Executive Officer	\$60,000 base	\$120,000 base	\$300,000 base	Bonus up to 10%; equity package subject to board approval
Chief Operating Officer* Automated	Included in Buildout	Included in Buildout	Included in Buildout	Performance bonus N/A
Chief Financial Officer* Automated	Included in Buildout	Included in Buildout	Included in Buildout	Performance bonus N/A
Head of AI / CTO* Monitoring	\$125,000-\$220,000	\$190,000-\$235,000	\$205,000-\$250,000	Bonus plus milestone-based equity

**Note:** \* Planned future hires. Actual timing should follow financing, acquisition closings, and workload needs.

## 18. Illustrative 3-Year Pro Forma Assumptions

The assumptions below are intended to support an internal planning model rather than serve as a formal forecast. Final projections should be rebuilt from diligence on identified acquisition targets, confirmed staffing plans, and actual product-development budgets. Insurance premiums are expected to decrease.

### Illustrative operating assumptions by year

Metric	Year 1	Year 2	Year 3
Acquisition count (cumulative)	1	2-3	4-5
Average acquired clinic annual revenue	\$1.2M-\$1.8M	\$3.3M-\$4.9M	\$5.4M-\$7.0M
Purchase price range	4.0x-5.0x EBITDA	4.0x-5.5x EBITDA	4.5x-6.0x EBITDA
Same-site organic growth	3%-5%	9%-12%	17%-24%
Administrative labor efficiency gain	0%-2%	3%-5%	5%-8%
Collections / billing improvement	1%-2% revenue benefit	2%-3% revenue benefit	2%-4% revenue benefit
Technology spend intensity	High build phase	Moderate build + pilots	More scaled / selective
Adjusted EBITDA margin goal	Near break-even to low-single digits	Mid-single digits	High-single to low-double digits

- No revenue from external software licensing is assumed until the platform demonstrates repeatable internal adoption and customer-ready packaging by each entity.
- Veterinary clinical judgment remains with licensed professionals; AI assumptions relate primarily to workflow automation, documentation support, monitoring, and analytics.
- Detection and autonomous-procedure applications are market ready and ready to gain revenues. The roadmap for automated medical procedures and applications and their near-term revenue drivers *may*

be impacted by regulatory approvals and until satisfied, may prevent revenue generation. This does not preclude training for the classical and quantum algorithms which may generate some revenues.

**Note:** The figures above are illustrative planning assumptions, not guarantees of future performance and not a substitute for a full integrated financial model.

Contact:

Wells Fargo Building  
Tampa, Florida  
United States of America

[rex@6r.ai](mailto:rex@6r.ai)

Phone - (917) 242-0913 Text us please.